Oncternal Therapeutics Inc
(NAS:ONCT)
$
4.17
-0.1991 (-4.56%)
Market Cap: 12.34 Mil
Enterprise Value: -8.26 Mil
PE Ratio: 0
PB Ratio: 0.78
GF Score: 39/100 Oncternal Therapeutics Inc (ONCT) Transcripts
- Q4 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMar 07, 2024$9.25 (-3.14%)Earnings
- Q3 2023 Oncternal Therapeutics Inc Earnings Call TranscriptNov 09, 2023$6 (-9.07%)Earnings
- Q2 2023 Oncternal Therapeutics Inc Earnings Call TranscriptAug 10, 2023$6.78 (-6.71%)Earnings
- Oncternal Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMay 04, 2023$6.32 (-3.60%)Earnings
- Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 TranscriptApr 03, 2023
- Q4 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMar 09, 2023$17.72 (-0.56%)Earnings
- Q3 2022 Oncternal Therapeutics Inc Earnings Call TranscriptNov 03, 2022$20 (-1.96%)Earnings
- Q2 2022 Oncternal Therapeutics Inc Earnings Call TranscriptAug 09, 2022$22.2 (-4.31%)Earnings
- Q1 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMay 05, 2022$22 (+1.85%)Earnings
- Q4 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMar 10, 2022$33.6 (-2.89%)Earnings
- Oncternal Therapeutics Inc Host Key Opinion Leader Webinar TranscriptJan 25, 2022
- Oncternal Therapeutics Inc to Announce Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab Call TranscriptJan 04, 2022
- Q3 2021 Oncternal Therapeutics Inc Earnings Call TranscriptNov 04, 2021$81.4 (+6.54%)Earnings
- Q2 2021 Oncternal Therapeutics Inc Earnings Call TranscriptAug 05, 2021$77.6 (+3.47%)Earnings
- Q1 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMay 06, 2021$109 (-9.02%)Earnings
- Q4 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMar 11, 2021$127.4 (+10.40%)Earnings
- Q2 2020 Oncternal Therapeutics Inc Earnings Call TranscriptAug 06, 2020$57.4 (-2.71%)Earnings
- Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell TranscriptJul 29, 2020
- Q1 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMay 07, 2020$50 (-5.87%)Earnings
- Q4 2019 Oncternal Therapeutics Inc Earnings Call TranscriptMar 16, 2020$66.6 (+3.26%)Earnings
- Q3 2019 Oncternal Therapeutics Inc Earnings Call TranscriptNov 07, 2019$115.6 (-3.99%)Earnings
- Q2 2019 Oncternal Therapeutics Inc Earnings Call TranscriptAug 08, 2019$88.6 (+3.75%)Earnings
- GTx, Inc and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Call TranscriptMar 07, 2019
- 1